SLC7A11 and glioblastoma: In glioblastoma (GBM) models, RSL3 activates NF‐κB signaling through GPX4 inhibition, subsequently suppressing ATF4/xCT system expression to exacerbate LPO [195].The application of NF‐κB inhibitor BAY 11‐7082 significantly attenuates the antitumor efficacy of RSL3 in vivo, highlighting the critical role of this pathway in ferroptosis.